StockGuide AI
Seguir acciones
EN RU ES
Ligand Pharmaceuticals

Ligand Pharmaceuticals

Precio: 254.57

Empresa y modelo de negocio

Ligand Pharmaceuticals is a biotechnology company focused on developing and commercializing technologies that enhance drug discovery and development. Its core products include a range of proprietary technologies and partnered programs that facilitate the creation of therapeutics across various disease areas. Major business segments include royalty revenue from partnered products and licensing agreements. The primary revenue sources stem from collaborations with pharmaceutical companies and royalties from sales of drugs utilizing Ligand's technologies.

Perfil de inversión

The investment profile of Ligand Pharmaceuticals is more aligned with value investors, given its current market position and revenue trends. The stock may appeal to those seeking potential long-term appreciation, although recent performance indicates challenges. Investors should consider the company's volatility and risk factors when evaluating their investment horizon.

Sitio oficial

Métricas fundamentales

EPS (TTM) — ganancias por acción de los últimos 12 meses, $
7.84 OK
Ingresos QoQ — crecimiento trimestral de ingresos
-13.3% ↓
Sorpresa EPS
-11.4% peor de lo esperado
Volatilidad 20d
1.8% estable
Datos FMP / FinFeed actualizados: 2026-06-11
Recomendación: Mantener Potencial: 65 Riesgo: 62 Actualizado: 2026-06-11 05:38
Cómo funciona la recomendación
Por qué la IA piensa así:
Strong price momentum, but declining revenue raises concerns.

Seguir en portafolio

Gráfico de precio

Recomendación IA Pronóstico de analista Evento de calendario Señal positiva Señal negativa Neutral / actualización Mantener / informativo B My buy S My sell
Cambios de recomendación IA
Fecha Antes Después Razón
2026-05-24 02:44 Vender Mantener Weak fundamentals and high risk limit upside potential.
2026-05-16 02:46 Mantener Vender Weak fundamentals and negative momentum raise concerns.
2026-05-08 15:20 — Mantener Weak fundamentals and negative momentum raise concerns.
Pronósticos de analistas
Fecha Analista Acción Objetivo Precio entonces
2026-04-30 10:09 H.C. Wainwright Objetivo aumentado 243 → 289 224.86
2026-04-28 11:36 RBC Capital Objetivo aumentado 235 → 252 241.79
2026-04-27 18:05 Stifel Nicolaus Objetivo aumentado 230 → 255 241.79